SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing intense volatility as investors react to a large-scale capital raise and concurrent equity offerings designed to fund a massive $39 billion backlog of AI server orders. While some community members are treating the resulting sell-off as a strategic buying opportunity driven by genuine demand, others remain deeply skeptical, expressing concerns over share dilution, management credibility, and the potential impact of ongoing regulatory scrutiny.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing downward pressure as investors react to the company's aggressive $40 billion financing plan to fund massive capital expenditures for AI infrastructure, despite the company posting strong earnings and a record-breaking $638 billion revenue backlog. The community remains deeply divided, with some investors aggressively buying the dip on the belief that the backlog and AI expansion create a long-term winner, while skeptics warn that the heavy debt and equity dilution are unsustainable burdens.

SpaceX

The upcoming SpaceX IPO is driving significant market volatility as investors rotate out of technology and semiconductor stocks to free up liquidity for the massive $75 billion offering. While the deal is heavily oversubscribed, community sentiment is sharply divided between believers in long-term space and AI infrastructure potential and skeptics warning of a classic exit-liquidity trap for retail participants.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors react to strong earnings and raised revenue guidance, fueling optimism about its core product growth and pipeline potential. Community sentiment remains bullish, with many focusing on the long-term blockbuster potential of its specialty pharmaceutical portfolio and the upcoming Phase 3 advancement of its pipeline assets.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market sentiment remains highly volatile as investors weigh ongoing geopolitical tensions in the Middle East against upcoming inflation data and central bank policy decisions. The community is actively debating the durability of recent relief rallies, with many questioning whether these moves are sustainable or merely short-term liquidity traps driven by algorithmic trading and election-year posturing.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF ($SMCX) is experiencing intense volatility and trading volume, driven by ongoing market concerns surrounding its underlying asset, SMCI, and high investor anxiety regarding potential delisting, reverse splits, and severe performance decay. Community discourse is deeply polarized, featuring active scalpers attempting to profit from sharp daily swings while many long-term holders express frustration over significant losses and the risks inherent in holding leveraged instruments amid negative news cycles.

Purecycle Technologies, Inc. engages in recycling waste polypropylene into virgin polymer. Its process includes two steps: Feed Pre-Processing and the use of the Technology for purification. The company was founded by John Scott in September 2015 and is headquartered in Orlando, FL.

PureCycle Technologies Inc

PureCycle Technologies is seeing heightened investor attention and bullish sentiment following a significant $395 million capital raise to restructure debt and fund long-term growth, coupled with positive technical momentum that has the community discussing potential squeeze scenarios. Traders are closely monitoring the company's progress in securing commercial orders and navigating regulatory certifications to validate its long-term viability in the recycling sector.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened market activity as traders debate its premium valuation and expansion strategy, with community sentiment split between concerns over high-multiple retail stocks and enthusiasm for the company's strong brand loyalty. Bullish participants are closely tracking potential technical breakouts and aggressive store openings, while skeptics emphasize margin pressures and the broader impact of persistent consumer inflation on discretionary coffee spending.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is gaining significant momentum as investors digest strong performance data from its prediction market platform and anticipate a surge in betting volume surrounding the upcoming World Cup and professional sports finals. The stock is currently the focus of intense community debate, with bulls citing a potential breakout and long-term tailwinds from expanded product offerings, while skeptics remain critical of management's history of underperformance and persistent volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining market attention following the appointment of Dr. Hubert C. Chen as Chief Medical Officer, a strategic move aimed at accelerating the development and potential commercialization of its lead obesity candidate, VK2735. The community is actively debating the company's competitive standing against major industry players, with investor sentiment focused on upcoming maintenance trial data and the ongoing speculation regarding potential partnership or acquisition opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering...

TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results

Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.

Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations

Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations...

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset...

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%

Key PointsRTW Investments bought 16,010,524 shares of Erasca last quarter; the estimated transaction value was $189.23 million based on the quarter's average share price...

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions...

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (Erasca or the Company) (NASDAQ:ERAS) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws and other unlawful business practices. [LEARN...

Erasca Stock Is Up 715%. Here's Why One Biotech Fund Still Bought $68 Million More

Erasca Stock Is Up 715%. Here's Why One Biotech Fund Still Bought $68 Million More...

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.11	--	--	N/A
Q1 '26	-$0.10	-$0.60	-475.31%	MISSED
Q4 '25	-$0.11	-$0.10	6.54%	BEAT
Q3 '25	-$0.10	-$0.11	-6.25%	MISSED
Q2 '25	-$0.12	-$0.12	-3.86%	MISSED

ERASErasca Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ERAS News